To evaluate factors predictive of survival following curative resection for node-negative gastric adenocarcinoma.
Results
Of 1,256 R0 resections performed, 507 (40%) were nodenegative, 465 were T1-T3, and 317 of these were adequately staged, as defined by histologic evaluation of at least 15 lymph nodes. Median age was 67 years, and 62% were male. Forty percent had T1 tumors, 34% were T2, and 26% were T3. Median tumor size was 3 cm. Vascular invasion (VI) was present in 17% of tumors and neural invasion (NI) in 31%. Extended (D2) lymphadenectomy was performed in 75% of cases. Five-and 10-year disease-specific survival rates were 79% and 67% respectively. Factors associated with poorer disease-specific survival on univariate analysis were male gender, serosal invasion, presence of VI, presence of NI, and resection other than distal subtotal gastrectomy. On multivariate analysis, NI was not an independent predictor of survival, but correlated directly with advancing T stage and tumor size.
Conclusions
Serosal invasion and presence of VI are strong predictors of poor survival in this disease. NI correlates with T stage and tumor size and may serve as a marker of advanced disease.
In adenocarcinoma of the stomach, presence or absence of lymph node metastases remains the most powerful predictor of survival following curative resection. [1] [2] [3] [4] Importantly, a significant proportion of patients with gastric cancer will be found to have node-negative disease on final histologic analysis. Appropriate staging of this disease, however, requires histologic evaluation of at least 15 lymph nodes in the resected specimen, as recognized by the 1997 AJCC staging system. 5 Thus, proper designation of nodenegative disease in gastric cancer relies on the combined efforts of skilled surgeons and scrutinizing pathologists.
Despite carrying a better overall prognosis, some nodenegative gastric cancer patients will have recurrence and die of disease. Identifying those factors associated with diseasespecific survival in adequately staged node-negative gastric cancer is important, as these patients are presumably free of microscopic regional metastases and may derive significant benefit from existing or future adjuvant strategies. Several reports have examined prognostic factors in patients with node-negative gastric cancer. 6 -10 All but one of these reports is from Eastern centers and the findings have not been corroborated in Western institutions, nor are they consistent.
A recent study examined the association of lymphatic or vascular microinvasion with survival in patients with advanced, node-negative gastric cancer. 10 Vascular invasion (VI) has been shown to predict poor outcome in several malignancies, including gastric cancer. [11] [12] [13] [14] [15] [16] [17] By contrast, presence of neural invasion (NI), which has demonstrated prognostic value in other malignancies, has not been examined in this group of patients. This analysis correlates his-tologic review with clinical information to identify factors associated with survival in a large group of patients with node-negative gastric cancer from a single Western center. Particular attention is given to presence or absence of microscopic VI and NI.
METHODS
From July 1985 through June 2001, 1,599 patients underwent resection for gastric adenocarcinoma at Memorial Sloan-Kettering Cancer Center (MSKCC). Their records were maintained in a prospective database. R0 resections were performed on 1,256 patients and 507 (40%) had node-negative disease, with 477 having invasive cancer on histologic examination. T4 patients (n ϭ 8) were reviewed but not used in the univariate and multivariate analyses due to limited sample size. Histologic reanalysis was not possible in four cases (one T1 lesion and three T3 lesions) because slides were unavailable. Thus, the final study population was 473 patients, of whom 465 were T1-T3. Breakdown by T stage was as follows: T1, n ϭ 188; T2, n ϭ 158; T3, n ϭ 119.
A separate analysis was performed on the subset of adequately staged patients (those with at least 15 lymph nodes evaluated in the resected specimen). This group included 317 patients, with the following breakdown: T1, n ϭ 118; T2, n ϭ 116; T3, n ϭ 83. Five of the eight T4 patients were adequately staged and were reviewed but again not included in the univariate or multivariate analysis due to limited sample size.
Patient demographics (age, gender), tumor characteristics (T stage, tumor size, tumor location, histologic grade, Lauren classification, presence of VI, presence of NI), treatment factors (type of gastric resection, extent of lymphadenectomy), and survival data were prospectively recorded. A standard gastrectomy encompassing N1 (perigastric) lymph nodes was defined as a D1 dissection, whereas complete removal of N2 (main arteries of the celiac axis, splenic hilus/pancreatic tail) lymph nodes was considered a D2 lymph node dissection. Table 1 demonstrates how variables  were stratified. Original slides, stained with hematoxylin and eosin (H&E), were obtained and reviewed by two independent pathologists. Confirmation of diagnosis, histologic grade, Lauren classification, and presence of VI was made. VI was defined as identification of tumor cell emboli within vascular channels of the tumor (Fig. 1A) . No specific distinction was given to whether the vessel was a lymphatic channel or a small venule, as this could not always be reliably determined. All specimens were carefully reviewed for the presence of NI, as defined by presence of tumor cells within the endoneurium or perineurium of the peripheral nerves (see Fig. 1B ). Absence of neoplastic cells in the vascular channels or perineural tissue resulted in the designation of VI negative or NI negative, respectively.
Statistical analyses were performed with SPSS statistical software, version 10.0 for Windows (Chicago, IL). Statistical significance was defined as P Ͻ .05. Disease-specific 
RESULTS

Entire Population
Patient Characteristics
The clinicopathologic factors of the entire population of T1-T3, R0 node-negative gastric cancer resections (n ϭ 465) are shown in Table 1 . There were 179 (38%) women and 286 (62%) men. The median age at operation was 67 years (range 27-96) for the entire group (67 years [range 30 -93] for men and 69 years [range 27-96 years] for women).
Tumor Characteristics
There were 188 (40%) T1 tumors, 158 (34%) T2 tumors, and 119 (26%) T3 tumors. Median tumor size was 3 cm (range 0.1-13). There were 220 (47%) proximal tumors (gastroesophageal junction and proximal third of stomach) and 245 (53%) distal tumors (mid-body and antrum). Two hundred thirty-three (50%) were low-grade and 231 (50%) were high-grade. Three hundred three (66%) were Lauren intestinal type and 160 (34%) were mixed or diffuse. VI was present in 80 cases (17%), NI was identified in 144 (31%), and 284 (61%) showed no evidence of VI or NI.
Treatment Characteristics
Gastric resections were categorized into four types: distal subtotal gastrectomy (DSG), proximal subtotal gastrectomy (PSG), esophagogastrectomy (EG), and total gastrectomy without esophagectomy (TG). Procedures were dichotomized as DSG or non-DSG for purposes of analysis. Two hundred six (44%) patients underwent DSG and the remainder underwent non-DSG procedures (n ϭ 259 [56%]; PSG, n ϭ 45 [10%]; EG, n ϭ 145 [31%]; TG, n ϭ 69 [15%]). Twenty-five percent of patients had less than a D2 lymphadenectomy (n ϭ 114) and the remaining 75% had a D2 dissection or greater (n ϭ 333). The mean number of nodes evaluated in the resected specimens was 23 Ϯ 14 (SD).
Survival
The median follow-up for the entire population was 36.3 months (range 1-193) from the time of resection. At the time of analysis, 304 (65%) patients were free of disease, 11 (3%) were alive with disease, 76 (16%) were dead from disease, 72 (15%) were dead from other causes, and 2 (1%) were lost to follow-up. The 5-and 10-year disease-specific survival (DSS) rates were 79 Ϯ 2% (SEM) and 67 Ϯ 4%, respectively ( Fig. 2 ). Median survival for the group was not reached by 10 years. No significant survival difference was observed between T1 and T2 tumors (5-year DSS 93 Ϯ 3% vs. 84 Ϯ 4%, P ϭ .09), but T3 tumors (serosally invasive) had significantly worse survival compared with both T1 and T2 lesions (5-year DSS 52 Ϯ 6%, P Ͻ .0001, Fig. 3 ). Other variables significant as negative predictors of survival on univariate analysis were male gender, tumor size at least 4 cm, proximal tumor location, presence of VI, presence of NI, and gastric resection other than a DSG (Table 2) . Age, histologic grade, Lauren classification, and type of node dissection had no bearing on survival in this analysis. On multi- variate analysis, male gender, serosal invasion, and presence of VI were identified as having independent associations with dying from disease in node-negative gastric cancer (see Table 2 ). Tumor size, site, presence of NI, and type of gastric resection did not demonstrate significant associations with DSS on multivariate analysis.
Adequately Staged Patients
Patient Characteristics
Based on the current AJCC staging requisite evaluation of 15 or more nodes in the resected specimen, there were 317 (68% of entire population) eligible patients. Their features are shown in Table 1 . There were 137 (43%) women and 180 (57%) men. Median age at time of resection was 68 years (range 27-96).
Tumor Characteristics
There were 118 (37%) T1, 116 (37%) T2, and 83 (26%) T3 lesions. Median tumor size was 3 cm (range 1-13). One hundred thirty-one (41%) were proximally located and 186 (59%) were mid-body or distal lesions. One hundred fiftysix (49%) were well differentiated and 161 (51%) were intermediate or poorly differentiated. Sixty-four percent (n ϭ 202) were Lauren intestinal type and 36% (n ϭ 115) were mixed or diffuse. VI was present in 53 cases (17%), NI was identified in 102 cases (32%), and 187 tumors (59%) displayed no evidence of microscopic VI or NI.
Treatment Characteristics
One hundred fifty-three patients (49%) underwent DSG and the remainder underwent PSG (n ϭ 30 [9%]), EG (n ϭ 79 [25%]), or TG (n ϭ 55 [17%]). Eighty-five percent (n ϭ 270) of adequately staged patients underwent formal D2 or greater lymphadenectomy, and 14% (n ϭ 44) had less than a D2 lymph node dissection. No information concerning type of lymphadenectomy was available for three patients. Average number of nodes evaluated in this cohort was 29 Ϯ 12, which is significantly more than the entire group by 6 nodes (P Ͻ .001).
Survival
The median follow-up for the adequately staged patients was 36.5 months (range 1-193) from the time of resection. At analysis, 217 (68%) were free of disease, 8 (2%) were alive with disease, 48 (15%) had died from disease, another 43 (15%) had died from other causes, and only 1 (Ͻ1%) was lost to follow-up. The 5-and 10-year DSS rates were 80 Ϯ 3% and 67 Ϯ 5%, respectively.
Factors bearing significant association with decreased survival on univariate analysis included male gender (P ϭ .05), serosal invasion (P Ͻ .0001), presence of VI (P ϭ .0001), presence of NI (P ϭ .003), and gastric resection other than a DSG (P ϭ .002). These results are shown in Table 3 . Variables showing no association with survival on univariate analysis included patient age, tumor location, tumor grade, Lauren classification, and type of lymphadenectomy. On multivariate analysis, including age at least 60, male gender, serosal invasion, tumor size at least 4.0 cm, presence of VI, presence of NI, and gastric resection other than a DSG, four factors remained independent negative predictors of survival: male gender, serosal invasion, presence of VI, and type of gastric resection. Advanced serosal invasion was the most powerful negative predictor of survival, followed closely by presence of VI.
Vascular and Neural Invasion
The incidences of VI and NI in adequately staged patients were 17% and 32%, respectively. Twenty-eight patients (9%) had evidence of VI only, 77 (24%) had evidence of NI only, the combination of VI and NI was seen in 25 patients (8%), and 187 patients (59%) had evidence of neither VI nor NI.
DSS for adequately staged patients with VI or NI is shown in Figure 4 . The 5-year DSS was 93 Ϯ 3% for patients without evidence of VI or NI, 73 Ϯ 6% for patients with NI only, 52 Ϯ 11% for patients with VI only, and 60 Ϯ 12% for those with evidence of both VI and NI by light microscopy (curve not included in Fig. 4 ).
Tumor size varied with presence or absence of NI ( Fig.  5 ). Mean tumor size (measured as largest diameter by the pathologist) was 3.53 Ϯ 0.20 cm (n ϭ 215) when NI was 
DISCUSSION
In 1993, Wanebo et al. reported a 35% survival rate for pathologically confirmed completely resected (R0) gastric adenocarcinoma from a database of 18,365 patients. 18 This finding was corroborated in more recent reports by Siewert et al. 1 and Hansson et al. 19 These and other large studies demonstrate that presence of lymph node metastases is the single most important prognostic finding in completely resected early and advanced gastric adenocarcinoma. 1, 2, 18, 20 Our study demonstrates that a significant proportion (40%) of Western patients undergoing R0 resection will have node-negative disease. Survival for this group of patients is remarkably better (DSS ϭ 79 Ϯ 2% at 10 years) than for their node-positive counterparts, irrespective of T stage. Some of these patients, however, will still go on to die of disease. Defining the biologic determinants of survival for patients with node-negative disease in a Western center was the primary objective of our study. Our second goal was to define the prognostic importance of neural invasion in this group of patients.
Proper staging of gastric cancer requires standard H&E histologic evaluation of at least 15 lymph nodes in the resected specimen to be considered N0, according to the fifth edition of the AJCC TNM classification. 5 This criterion remains unchanged in the recently released sixth edition. 21 The potential for stage migration has been confirmed via large retrospective reviews. 22, 23 In our analysis, 68% of node-negative patients were adequately staged. To minimize the impact of stage migration, an analysis of prognostic factors was performed on the subset of patients who had 15 or more nodes evaluated. A comparison of the entire population and those adequately staged is shown in Table 1 .
The groups differed in two respects: the extent of lymphadenectomy, as dictated by the operating surgeon, and the total number of nodes that were histologically evaluated. As can be expected, a greater percentage of extended lymphadenectomies were performed and a higher average node count was obtained in the subset of patients who were adequately staged. Other clinicopathologic variables were similar between the groups. Variables chosen for this analysis were based on findings in several Eastern series. Patient factors included age and gender. Age was stratified as a continuous variable, by the median and by the 60 years cutoff, as has been used in several previous studies. 7, 9, 10 Tumor variables included T stage, tumor size, tumor location, histologic grade, Lauren classification, and microscopic evidence of VI or NI. Tumor size was stratified as a continuous variable, by the median value of 3 cm, and by the cutoff of 4 cm, as previous used. 7, 10 Treatment variables included extent of gastric resection and type of lymphadenectomy. No consideration was given to perioperative adjuvant therapy, as less than 10% received additional treatment.
A summary of our findings compared to previous reports on node-negative gastric cancer reports is shown in Table 4 . Advanced T stage (or serosal involvement) was the most consistent negative predictor of survival in all reports, including ours. This is represented graphically in Figure 2 , where it is clear that patients with T3 tumors are far more likely to die of disease than those with T1 or T2 lesions (P Ͻ .0001).
The second most powerful independent predictor of poor outcome in this study was presence of VI. The incidence of VI was similar for T2-T4 tumors (20 -22%) and slightly lower in T1 tumors (9%); thus, the progression of gastric wall invasion appeared to have little bearing on the presence of this finding. Furthermore, mean tumor size was equivalent (3.99 vs. 3.93 cm) whether VI was present or absent in this study, suggesting that in node-negative gastric cancer, VI identifies biologically more aggressive lesions independent of tumor size or depth of invasion.
Maehara et al. reviewed 730 records of patients with node-negative disease between 1965 to 1990. 8 Similarly, they found VI present in 20% of specimens. Although the presence of VI was a significant finding on univariate anal- Node-Negative Gastric Cancer ysis, it was not an independent predictor of survival on multivariate analysis (see Table 4 ). In this study, patients were not stratified by number of nodes evaluated, as it was performed before acceptance of this staging method, so it is likely that some node-positive patients were included in their analysis. In addition, VI was not routinely evaluated before 1970 and data collection was not complete with respect to this variable. More recently, Hyung et al. reported their experience with VI in node-negative disease in Korea. 10 In this study only adequately staged patients with T2-T4 lesions were evaluated, and again, the incidence of VI was similar (20%). Their findings were similar to the observations of the current analysis with respect to the poorer prognosis associated with advanced T stage and presence of VI.
A possible explanation of why patients with VI are more likely to die from disease is that they are more prone to develop metastatic disease. 16 In one study of patients with advanced gastric cancer, 58% of patients with VI had lymph node metastases versus only 19% of patients without VI (P Ͻ .0001). 15 In this paper, an association was observed between VI and cellular proliferation as measured through DNA content, PCNA labeling, and AgNOR staining. The same group suggested mechanistically that VI-positive lesions have a higher level of intratumoral angiogenesis. 14 This may translate to a more aggressive phenotype. Studies in early gastric cancer have shown VI to predict development of lymphatic metastases but not to have an impact on survival, 6, 24 illustrating again that the presence of identifiable nodal disease is a more powerful predictor of survival in resectable gastric cancer. In our study, 12 of 118 adequately staged patients with T1 lesions had evidence of VI.
Five-year DSS was significantly reduced in those patients with tumors demonstrating histologic evidence of VI (57 Ϯ 4% vs. 97 Ϯ 2%, P Ͻ .001). Notably, this comparison does not consider node-positive early gastric cancer patients, as they were excluded from the analysis.
Several authors make a point of separating lymphatic channel and blood vessel involvement. True incidence is difficult to ascertain, as distinction between small lymphatic channels and capillaries is made by presence or absence of red blood cells and may not be accurate. In addition, since determination is made by reviewing portions of tumor tissue, sampling error may result in some inaccuracy. Thus, for this study, lymphatic channel invasion and blood vessel invasion were combined and designated as vascular invasion.
NI is known to be an indicator of poor outcome in cancers of the breast, biliary tract, colon and rectum, pancreas, prostate, skin, and others. [25] [26] [27] [28] [29] [30] [31] [32] [33] It is thought that cancer cells breach the perineurium at sites of vascular ingrowth and that this offers another potential route of dissemination. 16 Information of NI in gastric cancer is scant. In one report of 121 cases of advanced disease, presence of NI was associated with survival on univariate analysis but was not found to be an independent predictor on multivariate analysis. 34 A sec-ond study of 321 cases of gastric cancer (not stratified by nodal status) found an overall incidence of 45% and a correlation between T stage and presence of NI. 16 We observed both a correlation between T stage and presence of NI, as well as a correlation between presence of NI and tumor size (see Figs. 5 and 6 ). Thus, we speculate that NI represents a marker of advanced tumor stage, in contrast to the biologically aggressive phenotype suggested by VI.
We found no association between age and survival in node-negative gastric cancer, but we observed an independent association between male gender and poor prognosis. The recent report by Hyung et al. suggested such an association, although it failed to reach statistical significance. 10 Finally, we found that patients who underwent DSG had better survival than patients who underwent proximal subtotal, esophagogastric, or total gastrectomy. Interestingly, tumor site (proximal vs. distal) failed to demonstrate a significant association in this analysis. Perhaps this can be explained by the cohort of patients (n ϭ 42) who required total gastrectomy for large distal tumors, and the "distal" designation was thus less relevant than the procedure performed.
The question of extent of lymphadenectomy in nodenegative gastric cancer has been examined before. 6, 7, 35 We previously reported that extended lymphadenectomy (ՆD2) benefitted the subset of patients with T3N0 disease but did not benefit the node-negative group as a whole. 36 Our current report concurs with this finding in a larger number of patients and demonstrates an even greater survival advantage for adequately staged T3N0 patients (5-year survival 60% vs. 25%, P ϭ .03, data not shown). A recent analysis performed by the German Gastric Cancer Group suggested that D2 lymphadenectomy may benefit the T2 and T3 node-negative subsets of patients by removing micrometastases. 1 The value of this information, however, is clinically limited, as it remains impossible to determine nodal status preoperatively.
In conclusion, key findings in our study include the significance of VI as an independent negative prognostic factor in a large group of adequately staged node-negative gastric cancer patients from a single Western institution. We add the only evaluation of NI in node-negative gastric cancer in the literature. Presence of NI is directly related to tumor size and depth of invasion and may serve as a marker of advanced disease, while presence of VI probably suggests a biologically aggressive phenotype. Further work using tissue array technology may link histologic findings with molecular events to provide enhanced staging for gastric cancer in the future.
Discussion
DR. JOHN L. SAWYERS (Nashville, TN): Dr. David Kooby spent his last 2 years of general surgical residency at Vanderbilt, and I am pleased that he has continued to do clinical investigation. Dr. Murray Brennan was kind enough to send me a copy of his manuscript. And this is another valuable study by Dr. Brennan and his colleagues which adds additional information about gastric cancer to his previous reports in 1989, 1998, and 2000. He has the largest number of patients with gastric adenocarcinoma evaluated by prospectively maintained records in a single Western medical center. With the cooperation of his pathologists, who examined the resected specimens for tumor size, number of lymph nodes, vascular and neural invasion, the authors attempt to define the biologic determinants of survival for patients with node-negative disease.
Predictors of poor outcome even in node-negative patients were advanced T stage with serosal involvement and presence of vascular invasion, which in itself identified a more aggressive lesion. I was surprised to learn that neural invasion did not predict patient survival and served only to identify advanced disease.
Recent investigations with gene expressive profile seem to correlate with predictors of outcome. The last sentence in the author's manuscript hints that further work using tissue array technology may link histologic findings with molecular events to enhance staging for gastric cancer. Would you please elaborate on this very interesting statement? Did it include any gene expressive profiling?
What influences you to decide to perform a D1 or a D2 resection? Did the results of this study add to making this decision?
Finally, would you comment on the use of adjuvant therapy in patients with node-negative gastric cancer? Does the finding of vascular invasion, thought by your study to represent biologically aggressive phenotype, influence your decision regarding additional therapy?
This presentation is an important addition to our knowledge about gastric cancer, and I thank you for the privilege of commenting and reading your manuscript.
DR. MICHAEL A. CHOTI (Baltimore, MD): Let me congratulate Dr. Kooby, Dr. Brennan, Dr. Karpeh, and their coauthors on this interesting paper. This group, as Dr. Sawyers mentioned, has clearly taken a leadership position for gastric cancer in the Western world, with really the largest experience in their robust prospective database, as well as being thoughtfully analyzed.
In this report the authors addressed, as we heard, the clinically relevant question, that of node-negative gastric cancer. And I think we are seeing perhaps more of these as their frequency is going on. They report, as you saw, 40% of their group were node-negative resections in their experience. In addition to the large number in their series, the analysis specifically of these adequately staged (greater than 15 nodes) I think makes this report particularly relevant. I have several questions for the authors.
The first question relates to the pathologic evaluation of the nodes. Your study found an average of 23 nodes per specimen were identified even when including the less than D2 resections. Many of us still find that our pathologists report lesser numbers in spite the extent of resections we do, and often it is on the initial report and only after asking them to re-review it, we often get additional nodes. You mention in the manuscript that your pathologists reviewed all the specimens but don't comment on whether the nodes were re-reviewed. Were your nodal counts based on the initial pathology report, and did your subsequent pathology re-review actually include additional nodes? If so, what was the increased count?
Second, I found it interesting that on multivariate analysis as well, the type of gastrectomy-that is, distal subtotal versus total or proximal-was an independent significant predictor of long-term survival, particularly since the location of the tumor wasn't really found to be predictive (that is, proximal versus distal). Many of us believe that provided adequate margins and adequate node dissection is done, then the extent of resection shouldn't really matter, perhaps particularly in the node-negative settings. Could you comment on this point?
Lastly, I wonder if you could comment on the implications of the study of your recommendations regarding postoperative adjuvant therapy in the node-negative patient. As you know, randomized trials suggest the benefit of postoperative adjuvant therapy. Should perhaps T1 tumors with vascular invasion, should we offer them adjuvant postoperative therapy? Perhaps the T2, T3 tumors without vascular invasion may not derive a benefit from adjuvant therapy.
DR. RICHARD C. KARL (Tampa, FL): I would like to add my congratulations to the authors for this really remarkable paper. You have heard several discussants rise today to lament the small numbers of patients in some of these studies, and this is an example of the wisdom of prospectively collected data in a very busy center. They do some surgery up there in the Big Apple! Some of my questions are corollaries or repetitious of comments already made.
Since everybody is interested in the extent of resection that is necessary to adequately treat patients with gastric cancer, and you have sort of a natural experiment with patients who had less than 15 nodes retrieved (who tended to have smaller operations) and you make a comment in the manuscript about survival for T3N0 patients being 60% in those who were adequately staged and a third of that in those that weren't: can you draw some conclusions for us about the effect of extent of lymphadenectomy in patients who have N0 disease?
Second, to add to Dr. Sawyer's point about the molecular characteristics of these tumors that have vascular invasion, neural invasion, both or neither, I am sure there are some macroarrays floating around somewhere, and we would love to hear if you can identify any genes that may be expressed that can predict either one of these findings. Is there a difference in the pattern of recurrence in patients who have what you term aggressive disease-that is, vascular invasion-versus advanced disease with neural invasion? Do they fail in different ways?
I would like to also ask you if there is a difference between proximal and distal tumors, adding to Dr. Choti's point about the difference in the operation. Your second most frequently performed operation, as I read it, was esophagogastrectomy. The incidence of that disease, adenocarcinoma at or near the GE junction, is increasing. The other cancers appear to be decreasing. Can you make some comment about that? DR. MICHAEL EDWARDS (Little Rock, AR): I was surprised by the survival rate: it was better than I had anticipated. I do know that we cure some patients with gastric cancer, I just didn't think it was that many, percentage-wise. And I suspect that is the consensus of many here. Some infer that by doing a more extensive dissection, we cure more patients because of the therapeutic impact of a more complete lymphadenectomy or a more complete resection of the organ of origin. But in fact much of that perceived increase in survival, in this selected node-negative group, may in fact be due to a more detailed and accurate staging which alters the prevalence of disease in the various staging subsets.
There is a remarkable variance in the performance of lymphadenectomy in all sites, and particularly around the stomach. It would not surprise me that those staged negative with more lymph nodes analyzed had a much better prognosis. So I wanted to ask the authors: How much of this remarkably improved survival is because you winnowed out the people who are truly node-negative by this exhaustive surgical procedure and pathologic dissection of a specimen?
If this survival is truly genuine (and I know that it is, because this shows you the best we can achieve from patients who are truly, I think, nodenegative), we should be encouraged as surgeons to move forward, recognizing that the lion's share of the impact of the survival advantage gained is through the operation, and not through other modalities such as systemic chemotherapy. I would like the authors to comment on the relative discipline contributions to this outcome. I would also like to say that anything that we could do to standardize the staging part of the lymphadenectomy to know who is truly node-negative seems to me would be a good idea. Wouldn't it be wonderful if we could inject something in the stomach and actually identify the node that was most likely to give us that proper staging classification, to be able to tell the patient when they fit into that group with an 80% 5-year survival? So maybe there is a role for sentinel node staging of gastric cancer, and I would like the authors to comment. Thank you.
DR. THOMAS R. GADACZ (Augusta, GA): An excellent study and very good presentation. My question is directed regarding the failures and nonsurvivors. In those patients that had vascular invasion or tumor, was there a difference in how these patients died? Did those with an unfavorable T stage die primarily of a local recurrence? Did those with vascular invasion die primarily of metastatic disease? Were there any differences in these groups of patients? DR. MARSHALL M. URIST (Birmingham, AL): I too enjoyed this paper. I have just one practical question. If you have to analyze 15 lymph nodes to find out whether they are node-positive, how many nerves in cross section does the pathologist have to count? How many vascular spaces do they have to see in order to say that those two variables are also negative? DR. MARTIN KARPEH (New York, NY): To answer Dr. Sawyer's first question about the gene arrays, we have only just started to embark on this. One of the principal questions that we have asked is whether there are differences in the gene expression in tumors of the proximal and distal stomach and the distal esophagus. Along with that, we will be looking at patients who are node-positive and node-negative, but we are in the infancy of that evaluation.
As far as the indications for a D1 versus D2, our standard approach over the last 15 or 20 years has been a D2 lymphadenectomy, and our approach to the curative treatment of gastric cancer is to perform the D2 lymphadenectomy. Patients who have very early cancers do undergo a lesser lymphadenectomy. Patients who have had more extensive preoperative chemotherapy or are treated with palliative intent may have less than the D2, but our intent is to do a D2 in all these patients.
With regard to adjuvant therapy for the node-negative patient, I am sure you are aware of the prospective randomized trial that did show a 10% improvement in the patients that received postoperative chemotherapy and radiation after a gastrectomy. There were several issues with that trial. The first is that less than 10% underwent the D2 and greater than 50% had less than what would be considered a standard lymphadenectomy. So it is unclear as to the extent of resection those patients had going into the trial. Be that as it may, it was a positive trial in the background of a number of negative trials. Given the inconsistency of the data, proper staging becomes even more important. I think the surgeon is in the best position to help guide the patient with decisions regarding adjuvant therapy. Patients who are at high risk probably should receive postop adjuvant therapy, but for the node-negative patient at present we are not necessarily recommending it. With further data and better postop adjuvant therapy, patients with lymphatic invasion may certainly be candidates for such therapy.
Dr. Choti asked a number of questions regarding the path evaluation. We are fortunate to have a pathologist who is interested in pursuing better path staging. For a number of years we did pay a lot of attention to tagging the nodes to try to make sure that the pathologist knows what nodes are at risk and where to look. Now that the number of nodes has become the principal method of staging, the pathologists have now taken the impetus on themselves to adequately analyze the specimen for a number of nodes, so that we routinely get more than 15 as a standard. If we don't, we usually ask why. The node count was not redone when the pathologists reanalyzed this data. They principally reviewed the slides for lymphatic invasion. The number of nodes was taken from the pathology reports, so this was not reanalyzed.
The type of gastrectomy was an interesting finding that was unexpected.
We too are aware of the prospective randomized trials that have shown no difference in outcome based on the extent of gastrectomy. In this subset, gastrectomy did come out as a positive factor. The analysis was not controlled for the rate of complications. We do know that the larger cases are associated with a higher complication rate and that complications in and of themselves are associated with poorer outcome. So I think that may be one explanation for why the bigger operations resulted in poorer outcome. The questions by Dr. Karl, extent of lymphadenectomy, I think I answered that. We routinely do the D2. Obviously we don't know the extent of the nodal involvement at the time of surgery, and I think that this is one reason for doing the lymphadenectomy. You don't know what the extensive nodal involvement is, and by using one standard approach we can properly assess the extent of disease at the time of surgery.
Patterns of recurrence we did not look at in this study. We have looked at patterns of recurrence in the past. We do know that the earlier tumors, the T1 tumors, tend to recur in the distant fashion as opposed to a more local recurrence with the more advanced tumors. For the subset of nodenegative, we have not looked at specific patterns of recurrence.
As far as sentinel node and standardizing the staging, I certainly echo the comments that were made by Dr. Edwards. I think surgeons are in the prime position to adequately stage our patients and, therefore, give them the best advice as to whether adjuvant therapy is a meaningful avenue to pursue.
As far as, again, differences in patterns of recurrence, we did not look at that.
And just to finally end on Dr. Urist's question, all of these cases were analyzed pathologically in a standardized fashion. I think one of the beauties of this is that lymphatic invasion as a routine analysis that the pathologist does did turn out to be prognostically significant in these subgroups, so that no special studies are needed to get this information. Node-Negative Gastric Cancer
